Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP705174.RAVFVyE0MGLImyS2vATzhbE00jWm0teIQO37n3yUgLh3c130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP705174.RAVFVyE0MGLImyS2vATzhbE00jWm0teIQO37n3yUgLh3c130_provenance.
• NP651311.RA9qDKn2fRqvQYCkg6Xj2UZ9y1I0zB4GlNNJ3JYPIJO-4130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651311.RA9qDKn2fRqvQYCkg6Xj2UZ9y1I0zB4GlNNJ3JYPIJO-4130_provenance.
• NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
• assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1090946.RAebolw1PexIbqag1AYCGx4VC-MfVrDmQ03YX5aGvzAoc130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090946.RAebolw1PexIbqag1AYCGx4VC-MfVrDmQ03YX5aGvzAoc130_provenance.
• NP857933.RAufUUyL2O6jGoENCZoqpUz8jTrHWOhUwdEwIIo3Mid2o130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP857933.RAufUUyL2O6jGoENCZoqpUz8jTrHWOhUwdEwIIo3Mid2o130_provenance.
• NP595462.RAjDi2EMVW7gl3Uh0YdT_W3mLbfHvG2pukb4ExYhW7nXg130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP595462.RAjDi2EMVW7gl3Uh0YdT_W3mLbfHvG2pukb4ExYhW7nXg130_provenance.
• NP752486.RAhSXZwCZfKYes-dznj1Emj_wdaCsYXHcqHn4AesArf20130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP752486.RAhSXZwCZfKYes-dznj1Emj_wdaCsYXHcqHn4AesArf20130_provenance.
• NP873261.RAvBUdh1TOrHace5CMvkdqyqEE5QAkd5M70ORep_rbapg130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873261.RAvBUdh1TOrHace5CMvkdqyqEE5QAkd5M70ORep_rbapg130_provenance.
• NP937853.RALsc1gsErGirQAMUyJw2Tboa4yzYI92A33eB6CL113no130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP937853.RALsc1gsErGirQAMUyJw2Tboa4yzYI92A33eB6CL113no130_provenance.
• NP1090944.RAqSbxXetDeUOw6XnbdpeGGMO4e77nNtSZN63daSor0cg130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090944.RAqSbxXetDeUOw6XnbdpeGGMO4e77nNtSZN63daSor0cg130_provenance.
• NP1090947.RAlCTS3AYdb3LdIrlkJCH0M-drTQK2FXMeQm2Yq7mMteg130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090947.RAlCTS3AYdb3LdIrlkJCH0M-drTQK2FXMeQm2Yq7mMteg130_provenance.
• NP1090940.RAGuShsSJ9BapENuArC3vO06QLeY7-kgHHEECoYhrHuNo130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090940.RAGuShsSJ9BapENuArC3vO06QLeY7-kgHHEECoYhrHuNo130_provenance.
• NP1090941.RA47WECV-MR0talwyz8TbmULS3zrekwbJKTpSHPVUP47U130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090941.RA47WECV-MR0talwyz8TbmULS3zrekwbJKTpSHPVUP47U130_provenance.
• NP1090942.RAxE1XvgGJggMnq5UnjSRrb-Vp8SB8IMml7nwMNW2o6zA130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090942.RAxE1XvgGJggMnq5UnjSRrb-Vp8SB8IMml7nwMNW2o6zA130_provenance.
• NP1090943.RA4wD0i5lMm91Melom3QgCB0_MMAriUDsnfSyUIFi_hOU130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090943.RA4wD0i5lMm91Melom3QgCB0_MMAriUDsnfSyUIFi_hOU130_provenance.
• NP1090945.RAw0iZYrrLytMPvEuQa1vX1cnrO3zjHF6qNU7Yg-f-33E130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1090945.RAw0iZYrrLytMPvEuQa1vX1cnrO3zjHF6qNU7Yg-f-33E130_provenance.